| Literature DB >> 14654523 |
Richard Gorlick1, Peter Anderson, Irene Andrulis, Carola Arndt, G Peter Beardsley, Mark Bernstein, Julia Bridge, Nai-Kong Cheung, Jeffrey S Dome, David Ebb, Thomas Gardner, Mark Gebhardt, Holcombe Grier, Marc Hansen, John Healey, Lee Helman, Janet Hock, Janet Houghton, Peter Houghton, Andrew Huvos, Chand Khanna, Mark Kieran, Eugenie Kleinerman, Marc Ladanyi, Ching Lau, David Malkin, Neyssa Marina, Paul Meltzer, Paul Meyers, Deborah Schofield, Cindy Schwartz, Malcolm A Smith, Jeffrey Toretsky, Maria Tsokos, Leonard Wexler, Jon Wigginton, Stephen Withrow, Mason Schoenfeldt, Barry Anderson.
Abstract
Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials in this disease over the past several decades, and biology studies of tumor tissue have been an important study component. A meeting was held in Bethesda, Maryland on November 29-30, 2001, sponsored by the NIH Office of Rare Diseases, the Children's Oncology Group, and the National Cancer Institute-Cancer Therapy Evaluation Program with the general objectives: (a) to review the current state of knowledge regarding OS biology; (b) to identify, prioritize, and support the development of biology studies of potential clinical relevance in OS; and (c) to discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies. This report summarizes the information presented and discussed by the meeting participants.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14654523
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531